Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A rare case of intravascular epithelioid hemangioendothelioma of the cephalic vein treated with surgery and postoperative radiation therapy: a case report and review of the literature

  • Maria Paola Ciliberti1Email author,
  • Raffaella Caponio1,
  • Antonio Pascali1,
  • Gabriele Matichecchia1 and
  • Marco Lioce1
Journal of Medical Case Reports20159:91

https://doi.org/10.1186/s13256-015-0565-0

Received: 26 October 2014

Accepted: 4 March 2015

Published: 29 April 2015

Abstract

Introduction

Epithelioid hemangioendothelioma (EHE) is a rare endothelial tumor with an intermediate grade of malignancy. Few cases of primary vascular hemangioendothelioma have been described in the literature. Surgery is the treatment of choice, but radiation therapy and chemotherapy should also be considered in particular cases.

Case presentation

We present the case of a 44-year-old Caucasian woman affected by EHE of the cephalic vein, treated by complete surgical removal of the mass and postoperative local radiation therapy. At 5-year follow-up, our patient is alive, with no signs of local or distant relapse and with no late radiation-related effects.

Conclusions

Postoperative radiotherapy may play a role in cases in which tumor margins are close or cannot be assessed or when high-risk features are present.

Keywords

Epithelioid hemangioendothelioma Vascular Intravascular Radiotherapy Cephalic vein Review

Introduction

Epithelioid hemangioendothelioma (EHE) is a rare type of endothelial tumor that demonstrates an intermediate behavior between benign hemangioma and malignant angiosarcoma. It can occur in soft tissues, bones and visceral organs but also as a primary tumor of the blood vessel. About half of EHE are primary vascular. Differential diagnosis is often difficult, but recent diagnostic tools such as immunohistochemistry and mutation research can be useful for correct characterization. Surgery is the treatment of choice, but adjuvant treatment such as radiation therapy should be considered in the case of high-risk features or when complete removal is not feasible. Although sometimes promising, chemotherapy and antiangiogenetic agents do not have a well-established role. We report the case of intravascular EHE occurring in the cephalic vein of a 44-year-old woman, treated by surgery and postoperative radiation therapy (RT).

Case presentation

A 44-year-old Caucasian woman presented with a soft, painless, nonpulsatile, progressively enlarging mass at the level of the antecubital fossa of the left arm. A preliminary ultrasound (US) scan revealed an hypoechoic solid lesion along the cephalic vein, and a subsequent magnetic resonance image (MRI) of the arm confirmed a 2×1cm mass with a hypointense T1 signal and a weakly hyperintense T2 signal along the vein, suggesting a granuloma (Figure 1). Upon physical examination, the mass was mobile and painless; our patient did not present modification of reflexes of her left arm or signs of venous stasis. Our patient then underwent surgical removal of the neoplasm. Histology confirmed the diagnosis of intravenous EHE, defined as a ‘low-grade malignancy with moderate potential to recur locally or to metastatize’. Unfortunately, surgical margins were microscopically involved, so our patient underwent a second surgical operation: a 2cm segment of cephalic vein with a lozenge of skin was excised and replaced with a graft. The definitive histopathologic report confirmed the presence of microscopic residual foci of EHE, with free surgical margins. Our patient did not show any surgery-related impairment of her left arm functions. A post-surgery US study and MRI scan did not show any residual mass, while a total-body positron emission tomography-computed tomography (PET-CT) did not show any metastatic disease to regional lymph nodes or distant sites. Our patient was then referred to our radiation oncology unit. In consideration of the presence of microscopic disease foci in the second operation specimen and the considerable potential of local relapse highlighted by the pathologist, our patient underwent RT 4 months after the last surgery. A total dose of 54Gy in 27 fractions was administered with a single 6×6cm field. An 8MeV electron beam was used. Only a mild acute erythema of the irradiated skin was recorded as acute toxicity. During follow-up, our patient underwent MRI or ultrasound scans of the left arm every 6 months and computed tomography (CT) of the thorax and hepatic ultrasound scans every year. Five years after completion of the RT, our patient is alive with no evidence of recurrent or metastatic disease. She presented a Radiation Therapy Oncology Group (RTOG) grade 1 late toxicity in the irradiated skin (pigmentation changes).
Figure 1

The cephalic vein is occupied by a 2×1cm mass with a weakly hyperintense T2 signal (T2W TSI SPIR image).

Discussion

Hemangioendothelioma (HE) is a vascular neoplasm that shows intermediate biological behavior between benign hemangiomas and highly malignant angiosarcomas. It has the potential to metastatize or recur, although less frequently than classic angiosarcoma.

In the most recent World Health Organization (WHO) Classification [1] of soft tissue sarcoma, HE is included in the group of vascular tumors of the soft tissues and of the bones. Five subtypes of HE of soft tissues are considered: Kaposiform HE (included in the intermediate-locally aggressive group), retiform HE, composite HE, pseudomyogenic HE (included in the intermediate-rarely metastasizing group) and epithelioid HE, classified as a malignant tumor.

Pseudomyogenic (epithelioid sarcoma-like) HE was the first subgroup introduced in this classification. It usually occurs in young adult men on the limbs, presenting with multiple nodules. The spindle cells are characterized by a t(7;19) translocation [2].

Kaposiform HE is a locally aggressive neoplasm that involves superficial or deep soft tissues of children and teenagers; it has features common to both capillary hemangioma and Kaposi sarcoma, with several solid poorly circumscribed nodules composed of a mixture of small capillaries and solid lobules of endothelial cells arranged in a glomeruloid pattern [3]. It is often associated with consumptive coagulopathy (Kasabach-Merritt syndrome) and lymphangiomatosis [4].

Retiform HE most often occurs in the extremities of young adults as a slowly growing single cutaneous plaque or subcutaneous nodule microscopically characterized by interconnecting arborizing blood vessels arranged in a net-like pattern and minimal cytologic atypia [5]. It has a high frequency of local recurrence but a low metastatic potential [6].

The term ‘composite HE’ indicates a locally aggressive vascular neoplasm of low-grade malignancy showing varying combinations of benign, low-grade malignant, and high-grade malignant vascular components [7].

Epithelioid hemangioendothelioma (EHE) is probably the most aggressive histological subtype. It originates from the endothelium and most often occurs in adults of both sexes, but may rarely also affect children [8]. It was first described by Weiss and Enziger [9], after a review of 14 patients, as an intermediate entity between a benign hemangioma and a high-grade angiosarcoma. The largest series of 137 cases of liver EHE was reported by Makhlouf et al. [10].

Histopathological evaluation is central to the diagnosis of this tumor. Biopsy and immunohistochemical assays are essential to establish a clear diagnosis and to distinguish EHE from other histological types such as carcinoma, infectious processes, metastatic adenocarcinoma such as renal cell carcinoma, Ewing’s sarcoma, telangiectatic osteosarcoma, lymphoma or multiple myeloma (plasmatocytoma), hemangioma, epithelioid hemangioendothelioma, and angiosarcoma [11,12]. Corrin et al. first identified the angiogenic nature of these tumors based on the identification of Weibel-Palade bodies in a kind of lung neoplasia previously called ‘intravascular bronchioloalveolar tumor’ [13].

Microscopically, EHE produces a typical dense myxochondroid or myxohyaline matrix in which endothelial cells are embedded, arranged in short strings or nests [14]. Endothelial cells are polygonal, round or occasionally fusiform. Usually, mitotic activity is infrequent and nuclei are uniform, but about one-third of EHE could present anaplastic features with a high nuclear grade, necrosis and high mitotic activity. Due to its variable histological features, differential diagnosis can be difficult. Immunohistochemistry is a useful tool: EHE shows a typical endothelial phenotype, characterized by positivity to CD31, CD34 and von Willebrand factor, and occasionally to cytokeratins [15]. Recently, some studies have proposed new markers for vascular differentiation. For example, nuclear Fli-1, a protein expressed in endothelial cells as well as in T cells and megakaryocytes, was detected in 100% of cases in a series of 13 EHE and demonstrated a better sensitivity than CD34 and better specificity than CD31 [16]. Podoplanin, a transmembrane mucoprotein expressed in lymphatic endothelium, alveolar type I cells, osteoblasts and peritoneal mesothelial cells but not in normal vascular endothelial cells, is a useful marker to distinguish EHE from nonvascular tumors [17,18]. FKBP12, which inhibits Ca2+ and calmodulin-dependent calcineurin function, regulates B and T cell responses, and is expressed in both low- and high-grade vascular tumors, is expressed in well-differentiated areas of EHE [19]. An immunohistochemical panel [20] including FKBP12 combined with CD34 and CD31 allows a 93% diagnostic sensitivity of hemangioendothelioma.

A recurrent translocation t(1;3)(p36.23;q25.1), resulting in the fusion of CAMTA1 on 1p36.23 to WWTR1 on 3q25.1, has recently been identified in most EHE, even if in different sites and grades of malignancy [21,22]; this translocation has not been detected in other pathologies like epithelioid hemangioma, epithelioid angiosarcoma or pseudomyogenic (epithelioid sarcoma-like) HE, which often mimic EHE and make diagnosis more difficult. Another recurrent oncogenic activation secondary to TFE3 gene rearrangements and common fusion with YAP1 appears to be a distinctive subset of EHE occurring in young adults, with a clinically indolent course but a high propensity to metastasis [23]. Fluorescent in situ hybridization (FISH) or RT-PCR analysis for these fusions may be a useful molecular diagnostic tool in challenging diagnoses.

The etiology of EHE is not well known; however, predisposing factors for angiosarcoma have been suggested to include radiation, defunctionalized arteriovenous fistula, foreign bodies, carotid endarterectomy and intravascular prosthesis [24].

After a review of 30 patients with epithelioid EHE, Mentzel et al. found that, although this tumor histologically has low malignancy potential, metastatic disease occurs in 20 to 30% of patients and that overall EHE carries a risk of death of up to 17%; thus, the authors suggested that it should be considered a fully malignant, rather than borderline, vascular neoplasm [25]. Local recurrence occurs in about 10 to 15% of osseous EHE cases [12] after a relatively long period of latency. Half of the metastases occur in locoregional lymph nodes or lungs [26], so periodic CT scans of regional lymph nodes and lungs are recommended in the follow-up. However, patients with metastases could be treated with surgery and then survive for a long time: only 20% of them die due to the disease after 5 years [27] because half of all metastases are in the regional lymph nodes and could be easily controlled with local surgical excision [28]. Prognosis of EHE remains better than that of classic angiosarcoma, although it often remains variable and unpredictable.

Deyrup et al. analyzed 49 patients with EHE in an attempt to identify a method for stratifying risk of mortality. In univariate and multivariate analysis, increasing mitotic activity and size were significantly associated with higher mortality, while tumor site, cytologic atypia, the presence of necrosis and tumor spindling were not significant. The authors concluded that large tumors (>3cm) with high mitotic activity (>3 mitotic figures per 50 high power fields) had the worst prognosis with a 5-year disease-specific survival of 59% and an increased risk of metastases (up to 25%) [8].

Clinical presentation is variable, depending on the size and location of the tumor. EHE is often asymptomatic, especially when it involves visceral organs such as the lungs or liver. Nonspecific correlated symptoms can include fatigue, anorexia, nausea, or poor tolerance to exercise [29]. When a superficial vessel is involved, EHE can present as a painful soft mass.

Radiological assessment is the first approach to identifying EHE. The imaging technique used (MRI, CT, US) depends on the primary site of the tumor. Increased uptake of 18-F-fluorodeoxyglucose (FDG) in this tumor has recently been reported [30].

EHE can affect all vascularized tissues in any site, but most frequently involves superficial or deep soft tissues, bones [31,32] and visceral organs, in particular the liver [33] and lungs [34,35]. Cases of EHE have been described in almost all sites such as the skin [36,37], central nervous system [38-40], meninges [41], lips [42], gingiva [43,44], middle ear [45], thyroid gland [46], salivary glands [47], paranasal sinuses [48,49], breast [50], pleura [51-53], lymph nodes [54], mediastinum [55,56], heart [57-61], retroperitoneum [62], ileum [63-65], peritoneum [66], testis [67], bladder [68,69], penis [70], vulva [71], and so on. In 10% of cases the disease is multifocal [72].

Mortality varies depending on primary tumor site: the mortality range is 13% for EHE of soft tissues, 31% for EHE of the bone, 43% for EHE of the liver [10] and 65% for EHE of the lung [14].

Primary vascular EHEs represent about 50% of reported cases. They arise from a blood vessel [73], commonly small- to moderate-sized veins, such as the femoral, iliac or jugular veins, but also larger vascular structures such as the aorta or vena cava. Few cases originate from medium- to small-sized peripheral vessels. The intravascular subtypes are extremely rare [74].

Usually, EHEs present clinically as a painless elastic soft mass in the vicinity of a peripheral vessel causing symptoms and signs of deep venous occlusion, ranging from edema of the extremities, weakness and ischemia, to superior vein cava syndrome. Microscopically, they are associated with a blood vessel, usually a medium-sized vein [29], showing first an expansion of the affected blood vessel and then an involvement of the surrounding soft tissues, with a centrifugal proliferation pattern. It is often difficult to make a correct diagnosis in the early phase. This is partly because they are extremely rare and also because their imaging characteristics are nonspecific, resembling inflammatory or atherosclerotic lesions [24]. Ultrasonography is useful to define the morphology and vascularization of these masses and to evaluate blood flow, usually showing intraluminal defects and altered flow patterns, loss of plasticity and velocity increase [75]. On the other hand, MRI can give additional information about the involvement of surrounding soft tissues and cleavage planes, in addition to morphological features [27]. However, definitive radiological diagnosis is often hard, and only histological diagnosis can be conclusive.

Forty-three case reports on primary vascular EHE of both veins and arteries (except the aorta) have been described in the literature (Table 1). The involved vessels were the thoracic aorta [76,77], aortoiliac segment [78], radial artery [27], inferior vena cava [79-81] , superior vena cava [82-86], innominate vein [55,87-91], azygos vein [92-94], femoral vein [73,74,78,94-98], femoral artery [99] iliac veins [28,100,101], internal carotid artery [24], axillary vein [102], brachial vein [103] or artery [104-107], popliteal artery [108], pulmonary artery [109], occipital artery [110], temporal artery [111], meningeal artery [112], and digital artery [113]. Age of presentation ranged from 11 to 79 years (mean age was 39 years), and the distribution among the two sexes was almost equal, with a slight predominance of the female sex (59% vs. 41%). The diameter of the masses was variable, ranging from 0.5cm to 11cm. Almost all patients underwent surgical removal of the vascular EHE; in four cases resection was not complete, with macroscopic residual mass or microscopic positive margins. After treatment, patients were monitored for follow-up (2 to 108 months). Six patients (14%) developed distant metastases, especially liver and lung metastases, even if this occurrence did not always affect the overall survival when metastasectomy was performed. Three patients (7%) had local relapse, often in the cases treated by incomplete surgical removal; relapse was always treated with a second surgery. Postoperative RT was administered in only five cases, and chemotherapy in three patients.
Table 1

Cases of vascular epithelioid hemangioendothelioma described in literature

Author

Year

nr.pt

Sex

Age (yrs)

Artery/vein

Size (cm)

Primary therapy

R

Adjuvant therapy

Outcome

Notes

Follow-up (months)

Wu et al. [109]

2014

1

F

58

Right pulmonary artery

/

S

0

No

NED

 

24

Mlynski et al. [96]

2013

1

F

22

Femoral vein

/

S

0

No

M

Liver and lung metastases

12

Gundara et al. [79]

2013

1

M

39

IVC

4.5

S

0

No

NED

 

48

Henton et al. [105]

2013

1

F

39

Brachial artery

5

S

0

No

NED

 

12

Muñoz et al. [100]

2013

1

F

23

External iliac vein

1.7

S

0

No

NED

 

108

Muñoz et al. [100]

2013

1

M

44

External iliac vein

2

S

0

RT

M

NED after liver-lung metastasectomy

96

Li et al. [87]

2013

1

F

38

Innominate vein

4.2

S

0

CH

NED

 

18

Osawa et al. [24]

2012

1

M

59

Internal carotid artery

8

S

2

No

LR + M

Death 6 months after surgery

6

Nutthaki et al. [107]

2012

1

F

42

Brachial artery

1.7

S

0

No

/

 

/

De Palma et al. [92]

2012

1

M

47

Azygos vein

1

S

0

No

NED

 

12

Lahon et al. [82]

2012

1

F

29

SVC

4,5

S

0

No

NED

 

10

Fulton et al. [94]

2011

1

F

30

Femoral vein

4

S

0

No

M

Lung metastasis at diagnosis

8

Heldenberg et al. [108]

2011

1

F

32

Popliteal artery

3

S

0

No

/

 

/

Henriquez et al. [80]

2011

1

M

31

IVC

7

S

2

CH

RD

Second surgery R0

/

Namaoui et al. [83]

2011

1

F

25

SVC

8

S

0

No

NED

 

6

Minyi et al. [73]

2011

1

F

50

Common femoral vein

3

S

0

No

NED

 

12

Mansour et al. [55]

2010

1

M

35

Innominate vein

9.5

S

0

No

NED

 

30

Deedar et al. [102]

2010

1

M

53

Axillary vein

5.8

S

0

No

NED

 

/

Zhang et al. [5]

2010

1

F

71

Brachial artery/axillary artery

6.5

S

1

No

NED

 

/

El Demellay et al. [111]

2009

1

F

41

Temporal artery

0.5

S

0

No

NED

 

36

Scordi-Bello et al. [81]

2009

1

M

35

IVC

11

S

0

No

NED

 

10

Tayeb et al. [110]

2007

1

F

29

Occipital artery

/

S

0

/

NED

 

12

Aydin et al. [99]

2006

1

M

77

Femoral artery

6

S

0

No

NED

 

/

Kugai* et al. [97]

2006

1

F

69

Common femoral vein

/

S

/

/

/

 

/

Castelli et al. [27]

2005

1

M

26

Radial artery

3

S

0

No

/

 

/

Ludwikoski et al. [101]

2005

1

F

11

Iliac vein

/

S

/

/

M

Liver metastases

18

Hampers et al. [113]

2002

1

F

36

Palmar arch

2.5

S

0

No

NED

 

12

Isowa et al. [88]

2002

1

F

41

Innominate vein

3.4

S

0

No

NED

 

28

Schröder et al. [98]

2001

1

F

52

Femoral vein

4

S

0

No

NED

 

24

Charette et al. [95]

2001

1

M

23

Common femoral vein

2

S

0

No

NED

 

18

Ferretti et al. [84]

1998

1

M

79

SVC

3.5

S

2

/

/

Biopsy only

/

Reix et al. [74]

1998

1

F

16

Common femoral vein

2

S

0

No

NED

 

12

Moreno et al. [89]

1998

1

M

33

Innominate vein

6

S

0

RT

NED

Hystiocytoid hemangioma

7

Akashi et al. [104]

1997

1

F

67

Brachial artery

2

S

0

No

NED

 

40

Zingale et al. [103]

1993

1

M

47

Brachial vein

/

S

0

No

LR

NED after second surgery

21

Toursarkissian et al. [90]

1990

1

M

62

Innominate vein

/

S

0

RT

NED

 

54

Delin et al. [78]

1990

1

F

28

Common femoral vein

/

S

0

No

NED

 

6

Lamovec et al. [93]

1990

1

F

40

Azygos vein and SVC

5

S

0

RT + CH

NED

 

/

Nataf et al. [91]

1989

1

M

48

Azygos vein

2

S

2

No

RD

Palliative S (bypass) for the presence of spinal and lymph node invasion at diagnosis

/

Harris et al. [28]

1989

1

M

32

External iliac vein

2,5

S

0

RT

NED

 

12

De Verbizier et al. [86]

1987

1

F

57

SVC

/

none

/

No

PD

Surgery only on liver localization

6

Yousem et al. [85]

1987

1

F

35

SVC

10.5

S

0

No

NED

 

2

Enzinger** et al. [9]

1982

1

/

11

External iliac vein

/

S

/

/

M

 

18

*Only abstract available in English language; **not available online, abstract information only. /, not specified; M, male, F, female, IVC, inferior vena cava; SVC, superior vena cava; S, surgery; RT, radiotherapy; CH, chemotherapy; NED, no evident disease; LR, local relapse; M, metastases; R, residual tumor after surgery: 0 = no residual disease, 1 = microscopic residual cells, 2 = macroscopic residual mass; PD, progressive disease; RD, residual disease; LR, local relapse.

The treatment options for EHE include surgery, RT, and chemotherapy; new therapies such as antiangiogenetics agents have been also used. Few cases of spontaneous regression of EHE have been reported [114].

When feasible, surgery with free resection margins is the treatment of choice in the management of EHE. For example, partial hepatectomy [115] or orthotopic liver transplantation [116] represent the first treatment in primary hepatic tumors. Embolization of feeding vessels causing spontaneous regression of vascular tumors has been described [117]. When feasible, a wide resection is also recommended in primary bone EHEs. A preoperative selective embolization of involved vertebra may help to reduce intraoperative blood loss [118]. Surgery is the mainstay also in the treatment of primary vascular EHE. When reconstruction of the vessel is necessary, it can be done with prosthetic or autogenous interposition graft replacement [100]. A complete local excision of the neoformation with or without local lymphadenectomy is related to long-term survival.

A few patients have been treated with chemotherapy, often in the metastatic setting, but results are not always encouraging and response of EHE to chemotherapy seems to be low. The mainstay chemotherapeutic agents for metastatic EHE are doxorubicin and fluorouracil. Intensive regimens using combinations of vincristine, doxorubicin, ifosfamide, etoposide and cyclophosphamide have shown an increase in response rate, without an advantage in overall survival [10]. Doxorubicin in the pegylated liposomal formulation seems to lead to better responses [119] and reduce the risk of cardiotoxicity [120].

Due to the endothelial origin of EHE and the good response to therapies with interferon (IFN) alpha [121,122], recent therapeutic approaches have focused on the use of antiangiogenic agents [123]. Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor and seems to be an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas [124,125]. Thalidomide [126,127], lenalidomide [128], and endostar [129] are believed to have immunomodulatory and antiangiogenic properties; they also seem to be useful in the systemic treatment of EHE. Sorafenib [130] is also providing encouraging evidence of benefit.

Selective radionuclide therapy with intra-arterial injection of Yttrium (Y)-90 microspheres [131], commonly used for unresectable liver metastases and primary liver tumors with hopeful results, has shown some results in unresectable hepatic EHE.

In consideration of the high incidence of local relapse and the moderate radiosensitivity of EHE, RT has been used as adjuvant treatment in some high-risk cases, with good results. Hemangiomas involving the skeletal system have been treated effectively with local RT for many decades with a good long-term local control [132], even when RT is used as the only treatment option, such as in cases of surgically inaccessible sites [133].

Scott et al. [134] treated 14 patients affected by bone EHE with adjuvant or exclusive RT. The median dose administered was 54Gy for the patients treated with RT alone and 62.2Gy for the patients who underwent surgery, with a once daily (1.5 to 2Gy) or twice daily fractionation (1.2Gy). At a median follow up of 10.3 years, the 5-year local control, cause-specific survival, and overall survival rates were 100%, 86%, and 79%, respectively. No cases of late toxicity greater than G1 were recorded, suggesting that RT is a highly effective treatment option for this disease. Yin et al. [135] described a case of complete remission of a cervical spine EHE after the sole administration of 55Gy in 32 fractions over 43 days, using a 6MV photon three-field plan. No severe side effects were recorded, but the authors highlighted the risk of second malignancies. RT was also effective in obtaining a long-term local control when it was administered as adjuvant treatment [136], as in cases when complete surgical removal was not feasible [137,138]. No direct comparisons between surgery and radiotherapy have been published; however, high-dose radiotherapy seems to be curative when used as primary or adjuvant treatment in EHE of the spine [139,140]. Although re-resection is the treatment of choice in cases of EHE after surgery, RT showed efficacy also when administered as salvage therapy, as in the case of EHE of the mastoid described by Drazin et al.; the total dose administered at recurrence was 59.4Gy in 33 fractions. The patient was free from disease 8 years after surgery [48].

The role of RT in primary vascular EHE has not been established. Few data are available, and it is difficult to summarize guidelines about when this treatment should be performed, that is preoperatively, postoperatively, in the case of incomplete resection, or only at the moment of tumor progression. Hampers and Tomaino described the case of a patient with an EHE that presented as an aneurysm of the superficial palmar arch and third common digital artery [113]. The lesion was completely surgically removed and the patient received postoperative local irradiation to the hand because surgeons and pathologists could not verify tumor-free margins; dose and fraction size were not specified. The patient was free from local or distant recurrence at the 1-year follow-up evaluation. Muñoz et al. described a case of external iliac vein EHE with lymph node metastases treated by surgery and local RT [100]. Unfortunately, doses and volumes were not specified in the report. The patient was alive without local relapse at 8-year follow-up. Toursarkissian et al. described a case of EHE arising from the innominate vein treated with surgery and radiation therapy. The patient was alive at a 4.5-year follow-up without evidence of local relapse [90]. In the experience of Harris et al., an EHE of the external iliac vein with lymph-node involvement in a 32-year-old man was treated with surgery and adjuvant radiotherapy, because microscopic foci of the tumor were seen extending to the margins of the resection. The total dose administered was 66Gy, and the patient was free from relapse after 12 months [28].

Conclusions

Primary vascular EHEs are rare and publications in the worldwide literature are almost exclusively case reports. Primary vascular EHEs can occur in every age group. Surgery is the preferred treatment, when feasible. Chemotherapy is often used in cases of metastatic disease, with ambiguous results. The case reported here suggests that the addition of postoperative RT may be useful in cases where tumor margins are close or cannot be assessed, or those with high-risk features. Unfortunately, EHE behavior often remains unpredictable and unrelated to microscopic findings.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CT: 

computed tomography

EHE: 

epithelioid hemangioendothelioma

FDG: 

18-F-fluorodeoxyglucose

FISH: 

fluorescent in situ hybridization

HE: 

hemangioendothelioma

IFN: 

interferon

MRI: 

magnetic resonance imaging

PET-CT: 

positron emission tomography-computed tomography

RT: 

radiation therapy

US: 

ultrasonography

Declarations

Acknowledgments

We would like to thanks Caroline Oakley for her accurate revision.

Authors’ Affiliations

(1)
U.O. Radioterapia - National Cancer Research Centre - Istituto Tumori “Giovanni Paolo II”

References

  1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization Classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.Google Scholar
  2. Trombetta D, Magnusson L, von Steyern FV, Hornick JL, Fletcher CD, Mertens F. Translocation t(7;19)(q22;q13) – a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? Cancer Genet. 2011;204:211–5.PubMedGoogle Scholar
  3. Requena L, Kutzner H. Hemangioendothelioma. Semin Diagn Pathol. 2013;30:29–44.PubMedGoogle Scholar
  4. Fernández Y, Bernabeu-Wittel M, García-Morillo JS. Kaposiform hemangioendothelioma. Eur J Intern Med. 2009;20:106–13.PubMedGoogle Scholar
  5. Zhang G, Qianjin L, Yin H, Wen H, Yuwen S, Li D, et al. A case of retiform-hemangioendothelioma with unusual presentation and aggressive clinical features. Int J Clin Exp Pathol. 2010;3:528–33.PubMedPubMed CentralGoogle Scholar
  6. Calonje E, Fletcher CD, Wilson-Jones E, Rosai J. Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases. Am J Surg Pathol. 1994;18:115–25.PubMedGoogle Scholar
  7. McNab PM, Quigley BC, Glass LF, Jukic DM. Composite hemangioendothelioma and its classification as a low-grade malignancy. Am J Dermatopathol. 2013;35:517–22.PubMedGoogle Scholar
  8. Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol. 2008;32:924–7.PubMedGoogle Scholar
  9. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer. 1982;50:970–81.PubMedGoogle Scholar
  10. Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer. 1999;85:562–82.PubMedGoogle Scholar
  11. Evans HL, Raymond AK, Ayala AG. Vascular tumors of bone: a study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma. Hum Pathol. 2003;34:680–9.PubMedGoogle Scholar
  12. Christodoulou A, Symeonidis PD, Kapoutsis D, Iordanidis F. Primary epithelioid hemangioendothelioma of the lumbar spine. Spine J. 2008;8:385–90.PubMedGoogle Scholar
  13. Corrin B, Manners B, Millard M, Weaver L. Histogenesis of the so-called “intravascular bronchioloalveolar tumour”. J Pathol. 1979;128:163–7.PubMedGoogle Scholar
  14. de Albuquerque AKA C, de Oliveira Romano S, Eisenberg ALA. Epithelioid hemangioendothelioma: 15 years at the National Cancer Institute. Literature review. J Bras Patol Med Lab. 2013;49:119–25.Google Scholar
  15. Weissferdt A, Moran C. Primary vascular tumors of the lungs: a review. Ann Diagn Pathol. 2010;14:296e308.Google Scholar
  16. Gill R, O’Donnell RJ, Horvai A. Utility of immunohistochemistry for endothelial markers in distinguishing epithelioid hemangioendothelioma from carcinoma metastatic to bone. Arch Pathol Lab Med. 2009;133:967–72.PubMedGoogle Scholar
  17. Fujii T, Zen Y, Sato Y, Sasaki M, Enomae M, Minato H, et al. Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. Mod Pathol. 2008;21:125–30.PubMedGoogle Scholar
  18. Naqvi J, Ordonez NG, Luna MA, Williams MD, Weber RS, El-Naggar AK. Epithelioid hemangioendothelioma of the head and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol. 2008;2:25–30.PubMedGoogle Scholar
  19. Kösemehmetoğlu K, Gedikoğlu G, Ruacan S. Morphological and immunohistochemical features of malignant vascular tumors with special emphasis on GlUT1, and FkBP12 expressions. Turkish J Pathology. 2011;27:57–67.Google Scholar
  20. Higgins JP, Montgomery K, Wang L, Domanay E, Warnke RA, Brooks JD, et al. Expression of FKBP12 in benign and malignant vascular endothelium: an immunohistochemical study on conventional sections and tissue microarrays. Am J Surg Pathol. 2003;27:58–64.PubMedGoogle Scholar
  21. Mendlick MR, Nelson M, Pickering D, Johansson SL, Seemayer TA, Neff JR, et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol. 2001;25:684–68.PubMedGoogle Scholar
  22. Errani C, Zhang L, Shao SY, Hajdu M, Singer S, Maki RG, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644–53.PubMedPubMed CentralGoogle Scholar
  23. Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775–84.PubMedPubMed CentralGoogle Scholar
  24. Osawa S, Saito A, Shimizu H, Ogawa T, Watanabe M, Tominaga T. A case of intravascular epithelioid hemangioendothelioma occurring 14 years after coil embolization for an extracranial internal carotid artery aneurysm. J Vasc Surg. 2012;55:230–3.PubMedGoogle Scholar
  25. Mentzel T, Beham A, Calonje E, Katenkamp D, Fletcher CD. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol. 1997;21:363–74.PubMedGoogle Scholar
  26. Palsson B. Epitheloid hemangioendothelioma. Acta Oncol. 1999;38:659–61.PubMedGoogle Scholar
  27. Castelli P, Caronno R, Piffaretti G, Tozzi M. Epithelioid hemangioendothelioma of the radial artery. J Vasc Surg. 2005;41:151–4.PubMedGoogle Scholar
  28. Harris Jr EJ, Taylor Jr LM, Porter JM. Epithelioid hemangioendothelioma of the external iliac vein: a primary vascular tumor presenting as traumatic venous obstruction. J Vasc Surg. 1989;10:693–9.PubMedGoogle Scholar
  29. Ravi V, Patel S. Vascular sarcomas. Curr Oncol Rep. 2013;15:347–55.PubMedGoogle Scholar
  30. Treglia G, Ceriani L, Paone G, Rusca T, Bongiovanni M, Giovanella L. Multifocal epithelioid hemangioendothelioma of the lower limbs detected by 18F-FDG PET/MRI. Clin Nucl Med. 2015;40:352–4.Google Scholar
  31. Kerrya G, Marxa O, Krausb D, Vogelc M, Kaiserd A, Ruedingera C, et al. Multifocal epithelioid hemangioendothelioma derived from the spine region: case report and literature review. Case Rep Oncol. 2012;5:91–8.Google Scholar
  32. Tsuneyoshi M, Dorfman HD, Bauer TW. Epithelioid hemangioendothelioma of bone. Am J Surg Pathol. 1986;10:754–64.PubMedGoogle Scholar
  33. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107:2108–21.PubMedGoogle Scholar
  34. Jinghong X, Lirong C. Pulmonary epithelioid hemangioendothelioma accompanied by bilateral multiple calcified nodules in lung. Diagn Pathol. 2011;6:21.PubMedPubMed CentralGoogle Scholar
  35. Jang KY, Jin GY, Lee YC, Lee HB, Kang MJ, Choi HY, et al. Pulmonary epithelioid hemangioendothelioma: a tumor presented as a single cavitary mass. J Korean Med Sci. 2003;18:599–602.PubMedPubMed CentralGoogle Scholar
  36. Resnik KS, Kantor GR, Spielvogel RL, Ryan E. Cutaneous epithelioid hemangioendothelioma without systemic involvement. Am J Dermatopathol. 1993;15:272–6.PubMedGoogle Scholar
  37. Quante M, Patel NK, Hill S, Merchant W, Courtauld E, Newman P, et al. Epithelioid hemangioendothelioma presenting in the skin: a clinicopathologic study of eight cases. Am J Dermatopathol. 1998;20:541–6.PubMedGoogle Scholar
  38. Nora FE, Scheithauer BW. Primary epithelioid hemangioendothelioma of the brain. Am J Surg Pathol. 1996;20:707–14.PubMedGoogle Scholar
  39. Baehring JM, Dickey PS, Bannykh SI. Epithelioid hemangioendothelioma of the suprasellar area: a case report and review of the literature. Arch Pathol Lab Med. 2004;128:1289–93.PubMedGoogle Scholar
  40. Zheng J, Liu L, Wang J, Wang S, Cao Y, Zhao J. Primary intracranial epithelioid hemangioendothelioma: a low-proliferation tumor exhibiting clinically malignant behavior. J Neurooncol. 2012;110:119–27.PubMedGoogle Scholar
  41. Zheng J, Li P, Ma S, Geng M. Epithelioid hemangioendothelioma of the meninges mimicking metastatic carcinoma: a case report. Clin Neuropathol. 2013;32:324–7.PubMedGoogle Scholar
  42. Robinson AA, Tolentino LF, Uyanne J, Melrose R, Calhoun CC. Malignant epithelioid hemangioendothelioma of the lip: a case report and comprehensive literature review. J Oral Maxillofac Surg. 2014;72:695–701.PubMedGoogle Scholar
  43. Gordón-Núñez MA, Silva LM, Lopes MF, de Oliveira-Neto SF, Maia AP, Galvão HC. Intraoral epithelioid hemangioendothelioma: a case report and review of the literature. Med Oral Patol Oral Cir Bucal. 2010;15:e340–6.PubMedGoogle Scholar
  44. Wesley RK, Mintz SM, Wertheimer FW. Primary malignant hemangioendothelioma of the gingiva. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1975;39:103–12.PubMedGoogle Scholar
  45. Panda NK, Rao SS, Karuppiah S, Vaiphei K, Singh P. Epithelioid hemangioendothelioma of middle ear masquerading as glomus tumor. Am J Otolaryngol. 2007;28:69–71.PubMedGoogle Scholar
  46. Krisch K, Holzner JH, Kokoschka R, Jakesz R, Niederle B, Roka R. Hemangioendothelioma of the thyroid gland–true endothelioma or anaplastic carcinoma? Pathol Res Pract. 1980;170:230–42.PubMedGoogle Scholar
  47. Yoruk O, Erdem H, Mutlu V, Erdogan F, Altas E, Kantarci M. Epithelioid hemangioendothelioma of the submandibular gland. Auris Nasus Larynx. 2008;35:157–9.PubMedGoogle Scholar
  48. Drazin D, Gandhi R, Slodkowska E, Boulos AS. Epithelioid hemangioendothelioma of the mastoid: resection for recurrence and adjuvant radiation with 8-year followup. Case Rep Surg. 2013 (2013):469201, PMC. Web. 18 Mar. 2015 (Online publication only).Google Scholar
  49. Semino L, Pagella F, Delù G, Todeschini A, Luinetti O, Zappoli F, et al. Endoscopic treatment of ethmoidal hemangioendothelioma: case report and review of the literature. Am J Otolaryngol. 2006;27:287–90.PubMedGoogle Scholar
  50. Park SY, Lee JK, Jo S, Huh CH, Cho KH, Na JI. Cutaneous epithelioid hemangioendothelioma presented as an ulcerated areolar mass. J Dermatol. 2014;41:112–3.PubMedGoogle Scholar
  51. Márquez-Medina D, Samamé-Pérezvargas JC, Tuset-DerAbrain N, Montero-Fernández A, Taberner-Bonastre T, Porcel JM. Pleural epithelioid hemangioendothelioma in an elderly patient. A case report and review of the literature. Lung Cancer. 2011;73:116–9.PubMedGoogle Scholar
  52. Lee YJ, Chung MJ, Jeong KC, Hahn CH, Hong KP, Kim YJ, et al. Pleural epithelioid hemangioendothelioma. Yonsei Med J. 2008;49:1036–40.PubMedPubMed CentralGoogle Scholar
  53. Lazarus A, Fuhrer G, Malekiani C, McKay S, Thurber J. Primary pleural epithelioid hemangioendothelioma (EHE) – two cases and review of the literature. Clin Respir J. 2011;5(1):e1–5.PubMedGoogle Scholar
  54. Donato G, Conforti F, Allegra E. A rare case of primary nodal hemangioendothelioma. Oncol Lett. 2013;6:1759–61.PubMedPubMed CentralGoogle Scholar
  55. Mansour Z, Neuville A, Massard G. Mediastinal epithelioid haemangioendothelioma: a rare mediastinal tumour. Interact Cardiovasc Thorac Surg. 2010;10:122–4.PubMedGoogle Scholar
  56. Blanco M, Gil P, Jove P. Hemangioendotelioma epitelioide mediastínico simulando un teratoma. Arch Bronconeumol. 2011;47:376–7.PubMedGoogle Scholar
  57. Moulai N, Chavanon O, Guillou L, Noirclerc M, Blin D, Brambilla E, et al. Atypical primary epithelioid hemangioendothelioma of the heart. J Thorac Oncol. 2006;1:188–9.PubMedGoogle Scholar
  58. Messias P, Bernardo J, Antunes MJ. Primary left atrial haemangioendothelioma. Interact Cardiovasc Thorac Surg. 2008;7:945–6.PubMedGoogle Scholar
  59. Safirstein J, Aksenov S, Smith F. Cardiac epithelioid hemangioendothelioma with 8-year follow-up. Cardiovasc Pathol. 2007;16:183–6.PubMedGoogle Scholar
  60. Lisy M, Beierlein W, Müller H, Bültmann B, Ziemer G. Left atrial epithelioid hemangioendothelioma. J Thorac Cardiovasc Surg. 2007;133:803–4.PubMedGoogle Scholar
  61. Marchiano D, Fisher F, Hofstetter S. Epithelioid hemangioendothelioma of the heart with distant metastases. A case report and literature review. J. Cardiovasc Surg (Torino). 1993;34:529–33.PubMedGoogle Scholar
  62. Iimuro Y, Nakai N, Asano Y, Uyama N, Suzumura K, Nakai M, et al. Primary epithelioid hemangioendothelioma of the retroperitoneum: report of a case. Surg Today. 2012;42:1026–31.PubMedGoogle Scholar
  63. Akosa AB, Ali MH. Epithelioid hemangioendothelioma of terminal ileum after therapeutic irradiation. J Clin Pathol. 1989;42:889–90.PubMedPubMed CentralGoogle Scholar
  64. Li H, Shah D, Shah A, Qiu X, Cao D. Ileal malignant hemangioendothelioma as a hypervascular lesion on computed tomography scan. Int J Surg Case Rep. 2014;5:19–21.PubMedGoogle Scholar
  65. Yasuda S, Hashimoto T, Kanaizumi T, Kuwata H, Matsumoto I, Shiratori T. A case of hemangioendothelioma of the small intestine. Jpn J Surg. 1989;19:67–9.PubMedGoogle Scholar
  66. Mainenti PP, Romano L, Contegiacomo A, Romano M, Casella V, Cuccuru V. Rare diffuse peritoneal malignant neoplasms: CT findings in two cases. Abdom Imaging. 2003;28:827–30.PubMedGoogle Scholar
  67. Tsolos C, Polychronidis A, Sivridis E, Kelidis G, Simopoulos C. Epithelioid hemangioendothelioma of the testis. J Urol. 2001;166:1834.PubMedGoogle Scholar
  68. Geramizadeh B, Banani A, Foroutan H, Aminsharifi A, Karimi M. Malignant epithelioid hemangioendothelioma of the bladder: the first case report in a child. J Pediatr Surg. 2009;44:1443–5.PubMedGoogle Scholar
  69. Jain D, Sharma MC, Epari S, Gupta NP, Kolla SB. Hemangioendothelioma of urinary bladder - report of rare case. Urology. 2009;73:1259–61.PubMedGoogle Scholar
  70. Gharajeh A, Siemens DR, Isotalo PA, Nascimento AG, Borth CS. Multifocal penile epithelioid hemangioendothelioma masquerading as superficial penile vein thrombosis. Urology. 2006;68:673. e1–3.PubMedGoogle Scholar
  71. da Silva BB, Lopes-Costa PV, Furtado-Veloso AM, Borges RS. Vulvar epithelioid hemangioendothelioma. Gynecol Oncol. 2007;105:539–41.PubMedGoogle Scholar
  72. Haap M, Kötter I, Horger M, Thamer C, Wehrmann M, Häring HU, et al. Disseminated epitheloid hemangioendothelioma mimicking symptoms of systemic vasculitis. Onkologie. 2005;28:429–32.PubMedGoogle Scholar
  73. Minyi Y, Xintian H, Weimin L, Mier J. Intravascular epithelioid hemangioendothelioma. Int Angiol. 2011;30:181–4.PubMedGoogle Scholar
  74. Reix T, Sevestre H, Sevestri-Pietri MA, Szychta P, Pietri J. Primary malignant tumors of the venous system in the lower extremities. Ann Vasc Surg. 1998;12:589–96.PubMedGoogle Scholar
  75. Louail B, Vautier-Rodary R, Gondry-Jouet C, Westeel A, Filloux-Morfaux V, Auquier M, et al. Value of imaging in early diagnosis of peripheral vein tumors. J Radiol. 1998;79:1387–91.PubMedGoogle Scholar
  76. Shijubo N, Nakata H, Sugaya F, Imada A, Suzuki A, Kudoh K, et al. Malignant hemangioendothelioma of the aorta. Intern Med. 1995;34:1126–9.PubMedGoogle Scholar
  77. Traverse JH, Lesser JR, Flygenring BP, Bracken TH, Olevsky OM, Nicoloff DM, et al. Epithelioid hemangioendothelioma of the thoracic aorta resulting in aortic obstruction and congestive heart failure. Circulation. 1999;100:564–5.PubMedGoogle Scholar
  78. Delin A, Johansson G, Silfverswärd C. Vascular tumours in occlusive disease of the iliac-femoral vessels. Eur J Vasc Surg. 1990;4:539–42.PubMedGoogle Scholar
  79. Gundara JS, Gill AJ, Neale M, Collins PJ, Hugh TJ, Samra JS. Inferior vena cava epithelioid hemangioendothelioma. J Vasc Surg. 2013;1:75–7.PubMedGoogle Scholar
  80. Henriquez CR, Cazes A, Fabiani JN, Bruneval P. Epithelioid hemangioendothelioma of the inferior vena cava. Ann Pathol. 2011;31:218–21.PubMedGoogle Scholar
  81. Scordi-Bello IA, Snyder A, Schwartz M, Fallon JT. Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol. 2009;18:243–6.PubMedGoogle Scholar
  82. Lahon B, Fabre D, De Montpreville V, Dartevelle P. Epithelioid haemangioendothelioma of the superior vena cava. Interact Cardiovasc Thorac Surg. 2012;15:186–7.PubMedPubMed CentralGoogle Scholar
  83. Namaoui RY, Marcheix B, Zohra MF, Bonnet V, Delisle MB, Gomez-Brouchet A. An exceptional tumor of the vena cava. Ann Pathol. 2011;31:406–8.PubMedGoogle Scholar
  84. Ferretti GR, Chilles C, Woodruff RD, Choplin RH. Epithelioid hemangioendothelioma of the superior vena cava: computed tomography demonstration and review of the literature. J Thorac Imaging. 1998;13:45–8.PubMedGoogle Scholar
  85. Yousem SA, Hochholzer L. Unusual thoracic manifestations of epithelioid hemangioendothelioma. Arch Pathol Lab Med. 1987;111:459–63.PubMedGoogle Scholar
  86. de Verbizier G, Gasquet C, Barret D, Drouineau J, Poncin E, Touchard G, et al. Epithelioid hemangioendothelioma of the liver and superior vena cava. Radiological results apropos of a case in an adult. J Radiol. 1987;68:55–9.PubMedGoogle Scholar
  87. Li XM, Lin XY, Xu HT, Yu JH, Wang L, Fan CF, et al. Mediastinal epithelioid hemangioendothelioma with abundant spindle cells and osteoclast-like giant cells mimicking malignant fibrous histiocytoma. Diagn Pathol. 2013;8:103.PubMedPubMed CentralGoogle Scholar
  88. Isowa N, Hasegawa S, Mino M, Morimoto K, Wada H. Mediastinal epithelioid hemangioendothelioma resected by hemi-plastron window technique. Ann Thorac Surg. 2002;74:567–9.PubMedGoogle Scholar
  89. Moreno A, Asunción Cañadas M, Minguella J, Torras J. Histiocytoid hemangioma of the innominate vein. Pathol Res Pract. 1988;183:785–91.PubMedGoogle Scholar
  90. Toursarkissian B, O’Connor WN, Dillon ML. Mediastinal epithelioid hemangioendothelioma. Ann Thorac Surg. 1990;49:680–5.PubMedGoogle Scholar
  91. Nataf P, Regnard JF, Solvignon F, Bruneval P, Faucher JN, Levasseur P. Epithelioid hemangioendothelioma of the azygos vein. Arch Mal Coeur Vaiss. 1989;82:1919–22.PubMedGoogle Scholar
  92. De Palma A, Pagliarulo V, Ardò N, Loizzi D. Surgical treatment of a rare case of epithelioid hemangioendothelioma of the azygos vein. Interact Cardiovasc Thorac Surg. 2012;14:91–3.PubMedGoogle Scholar
  93. Lamovec J, Sobel HJ, Zidar A, Jerman J. Epithelioid hemangioendothelioma of the anterior mediastinum with osteoclast-like giant cells. Light microscopic, immunohistochemical, and electron microscopic study. Am J Clin Pathol. 1990;93:813–7.PubMedGoogle Scholar
  94. Jain A, Fulton JJ. A rare vascular tumor presenting as persistent pain at the site of a chronic DVT. J Vasc Surg. 2011;54(6):1861.Google Scholar
  95. Charette S, Nehler MR, Whitehill TA, Gibbs P, Foulk D, Krupski WC. Epithelioid hemangioendothelioma of the common femoral vein: case report and review of the literature. J Vasc Surg. 2001;33:1100–3.PubMedGoogle Scholar
  96. Mlynski J, Domont A, Mallios S, Bonvalot S. Fukui. Epithelioid hemangioendothelioma of the femoral vein in a 22-year-old female. EJVES Extra. 2013;25:e1–2.Google Scholar
  97. Kugai T. Epithelioid hemangioendothelioma of the remnant femoral vein associated with a persistent sciatic vein. Jpn J Vasc Surg. 2006;15:387–90.Google Scholar
  98. Schröder A, Peters A, Riepe G, Larena A, Meierling S, Mentzel T, et al. Vascular tumors simulating occlusive disease. Vasa. 2001;30:62–6.PubMedGoogle Scholar
  99. Aydin H, Koçer B, Erekul S, Sakinci U. Epithelioid hemangioendothelioma on left femoral artery after multiple femoral artery interventions. EJVES Extra. 2006;11:112–4.Google Scholar
  100. Muñoz A, Diaz-Perez JA, Romero-Rojas AE, Hernandez E, Martin-Berdazco F. Report of 2 cases of primary epithelioid hemangioendothelioma of the external iliac vein. Vasc Endovascular Surg. 2013;47:474–8.PubMedGoogle Scholar
  101. Ludwikowski B, Jones N. Epithelioid hemangioendothelioma of external iliac vein with multiple metachronous localisations in liver and lung. Abstract book of the 9th International Danube Symposuium of Pediatric Surgery; 2005 20-22 Oct; Vienna, Austria. Available on http://www.kidsdoc.at/va_donausymposium_abstracts.html.
  102. Deedar-Ali-Khawaja R, Fatimi SH, Shahabuddin S. Epithelioid hemangioendothelioma of axillary vein: an imminent vascular tumor? Am Surg. 2010;76:e176–7.PubMedGoogle Scholar
  103. Zingale A, Bruno G, Giuffrè F, Carpinteri M, Albanese V. Hemangioendothelioma mimicking a median nerve neoplasm. Case report. J Neurosurg Sci. 1993;37:119–22.PubMedGoogle Scholar
  104. Akashi K, Yasuda M, Suto R, Fukuda H, Itoh J, Tsutsumi Y, et al. A case of epithelioid hemangioendothelioma associated with an artery. Tokai J Exp Clin Med. 1997;22:65–9.PubMedGoogle Scholar
  105. Henton JM, Kang N. Epithelioid hemangioendothelioma: occasionally encountered and potentially harmful. J Plast Reconstr Aesthet Surg. 2013;66:131–3.PubMedGoogle Scholar
  106. Zhang J, Wang Y, He X, Lu N, Xu D. Epithelioid hemangioendothelioma adjacent to the axilla: a case report. Chin Ger J Clin Oncol. 2010;9:359–61.Google Scholar
  107. Nuthakki S, Fessell D, Lal N, Shirkhoda A, Irwin T, Irwin R. Epithelioid hemangioendothelioma mimicking a nerve sheath tumor clinically and on MR imaging. Skeletal Radiol. 2007;36 Suppl 1:S58–62.PubMedGoogle Scholar
  108. Heldenberg E, Rabin I, Cheyn D, Lorber J, Elkabetz E, Sandbank J, et al. Epithelioid hemangioendothelioma as a rare cause of blue toe syndrome. J Vasc Surg. 2011;54:854–6.PubMedGoogle Scholar
  109. Wu XN, Chen MJ, Li DQ, Hu JG, Yu FL. Pulmonary artery pseudoaneurysm caused by a rare vascular tumor: epithelioid hemangioendothelioma. Thorac Cardiovasc Surg. 2014;62:92–4.PubMedGoogle Scholar
  110. Tayeb T, Bouzaiene M. Epithelioid hemangioendothelioma mimicking an occipital artery aneurysm. Rev Stomatol Chir Maxillofac. 2007;108:451–4.PubMedGoogle Scholar
  111. El Demellawy D, Nasr A, Alowami S. Epithelioid hemangioendothelioma of the temporal artery presenting as temporal arteritis: case report and literature review. Rare Tumors. 2009;1:e20.PubMedPubMed CentralGoogle Scholar
  112. Koh YC, Yoo H. Epithelioid haemangioendothelioma of the sphenoid bone. J Clin Neurosci. 2001;Suppl 1:63–6.Google Scholar
  113. Hampers DA, Tomaino MM. Malignant epithelioid hemangioendothelioma presenting as an aneurysm of the superficial palmar arch: a case report. J Hand Surg Am. 2002;27:670–3.PubMedGoogle Scholar
  114. Cronin P, Arenberg D. Pulmonary epithelioid hemangioendothelioma: an unusual case and a review of the literature. Chest. 2004;125:789–93.PubMedGoogle Scholar
  115. Bouslama K, Houissa F, Rejeb MB, Bouzaidi S, Moualhi L, Mekki H, et al. Malignant epithelioid hemangioendothelioma: a case report. Oman Med J. 2013;28:135–7.PubMedPubMed CentralGoogle Scholar
  116. Akça S, Süleymanlar I, Dinçer D, Demirbaş A, Gelen T, Gürkan A, et al. Hepatic epithelioid hemangioendothelioma treated with orthotopic liver transplantation: a case report. Turk J Gastroenterol. 2002;13:221–5.PubMedGoogle Scholar
  117. Samuel M, Spitz L. Infantile hepatic hemangioendothelioma: the role of surgery. J Pediatr Surg. 1995;30:1425–9.PubMedGoogle Scholar
  118. Aflatoon K, Staals E, Bertoni F, Bacchini P, Donati D, Fabbri N, et al. Hemangioendothelioma of the spine. Clin Orthop Relat Res. 2004;418:191–7.PubMedGoogle Scholar
  119. Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma. 2008;8:21–32.PubMedGoogle Scholar
  120. Grenader T, Vernea F, Reinus C, Gabizon A. Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin. J Clin Oncol. 2011;29:e722–4.PubMedGoogle Scholar
  121. Niemelä M, Mäenpää H, Salven P, Summanen P, Poussa K, Laatikainen L, et al. Interferon alpha-2a therapy in 18 hemangioblastomas. Clinical Cancer Res. 2001;7:510–6.Google Scholar
  122. Palmieri G, Montella L, Martignetti A, Bianco AR. Interferon α-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report. Oncol Rep. 2000;7:145–9.PubMedGoogle Scholar
  123. Calabrò L, Di Giacomo AM, Altomonte M, Fonsatti E, Mazzei MA, Volterrani L, et al. Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res. 2007;26:145–50.PubMedGoogle Scholar
  124. Gaur S, Torabi A, O’Neill TJ. Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report. Cancer Biol Med. 2012;9:133–6.PubMedPubMed CentralGoogle Scholar
  125. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257–63.PubMedGoogle Scholar
  126. Raphael C, Hudson E, Williams L, Lester JF, Savage PM. Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report. J Med Case Rep. 2010;4:413.PubMedPubMed CentralGoogle Scholar
  127. Mascarenhas RC, Sanghvi AN, Friedlander L, Geyer SJ, Beasley HS, Van Thiel DH. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology. 2004;67:471–5.PubMedGoogle Scholar
  128. Sumrall A, Fredericks R, Berthold A, Shumaker G. Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease. J Neurooncol. 2010;97:275–7.PubMedGoogle Scholar
  129. Ye B, Li W, Feng J, Shi JX, Chen Y, Han BH. Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: report of three cases and review of the literature. Oncol Lett. 2013;5:1491–6.PubMedPubMed CentralGoogle Scholar
  130. Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119:2639–44.PubMedGoogle Scholar
  131. Laçın S, Küçük O, Oz I, Bılgıç S. Selective intra-arterial Y-90 microsphere therapy in hemangioendothelioma. Turk J Gastroenterol. 2011;22:89–92.PubMedGoogle Scholar
  132. Biswal BM, Rath GK, Sandhu M, Rastogi S. Radiotherapy in symptomatic skeletal hemangiomas. Indian J Radiol Imaging. 1995;5:157e159.Google Scholar
  133. Brennan J, Midha R, Ang L, Perez-Ordonez B. Epithelioid hemangioendothelioma of the spine presenting as cervical myelopathy: case report. Neurosurgery. 2001;48:1166–9.PubMedGoogle Scholar
  134. Scott M, Indelicato DJ, Morris CG, Gibbs C, Scarborough MT, Reith JD, et al. Radiotherapy for hemangioendothelioma: the University of Florida experience. Int J Radiat Oncol Biol Phys. 2011;81:S634–5.Google Scholar
  135. Yin KL, Sumathi VP, Spooner D. Radiotherapy as an effective primary treatment for epithelioid hemangioendothelioma of the cervical spine. Anticancer Res. 2012;32:4597–600.Google Scholar
  136. Gherman CD, Fodor D. Epithelioid hemangioendothelioma of the forearm with radius involvement. Case report. Diagn Pathol. 2011;6:120.PubMedPubMed CentralGoogle Scholar
  137. Watanabe T, Saito N, Shimaguchi H, Fujimaki H, Kamiya M, Nakazato Y, et al. Primary epithelioid hemangioendothelioma originating in the lower petroclival region: case report. Surg Neurol. 2003;59:429–33. discussion 434.PubMedGoogle Scholar
  138. Themistocleus GS, Papagelopoulos PJ, Petraki KD, Stilianessi EV, Partsnevelos AA, Sapkas GS. A 23-year-old woman with complete paraplegia and anesthesia below the T8 level. Clin Orthop Relat Res. 2005;430:258–65.Google Scholar
  139. Kleer CG, Unni KK, McLeod RA. Epithelioid hemangioendothelioma of bone. Am J Surg Pathol. 1996;20:1301–11.PubMedGoogle Scholar
  140. Wold LE, Unni KK, Beabout JW, Ivins JC, Bruckman JE, Dahlin DC. Hemangioendothelial sarcoma of bone. Am J Surg Pathol. 1982;6:59–70.PubMedGoogle Scholar

Copyright

© Ciliberti et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement